Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis.
Antihistamines are the pharmacologic cornerstone of treatment for allergic rhinitis. The comparative effects of the newer, more specific H (1) -antagonists cetirizine and loratadine among younger patients are not well characterized. The efficacy and safety of cetirizine and loratadine were compared in a prospective, randomized, double-blind, longitudinal, parallel-group study of 80 children, 2 to 6 years of age, with perennial allergic rhinitis caused by house dust mites or plant pollens (verified by a radioallergosorbent or skin test). Patients received cetirizine or loratadine at 0.2 mg/kg once daily in the morning for 28 days. Histamine skin tests and eosinophil counts from nasal smears were performed at baseline and at the end of treatment. Individual rhinitis symptoms were assessed by the investigator at baseline and on day 28 and by parents at baseline and daily in symptom diaries. Global assessments were made by using a visual analog scale at baseline and at the end of treatment. Cetirizine produced significantly greater inhibition of the wheal response compared with loratadine (P <.0001). Eosinophil counts were improved to a comparable degree with both agents. Cetirizine and loratadine produced comparable improvements in symptoms and according to a global evaluation as assessed by the investigator at the end of treatment. Both agents produced substantial symptomatic relief according to patients' daily diary assessments; however, cetirizine was more effective than loratadine in relieving the symptoms of rhinorrhea, sneezing, nasal obstruction, and nasal pruritus (P <. 0001). Both treatments were well tolerated; two patients receiving cetirizine were dropped from the study because of adverse events. Cetirizine and loratadine provided effective, well-tolerated relief of the symptoms of perennial allergic rhinitis in small children. Cetirizine was more effective than loratadine in inhibiting the wheal response to histamine challenge and afforded greater reductions in most individual symptoms assessed daily by the parent.
Sienra-Monge
J J
JJ
Pulmonology and Allergy Department, Hospital Infantil de Mexico Federico Gómez, Mexico.
Gazca-Aguilar
A
A
Del Rio-Navarro
B
B
D017332:Cetirizine / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D004311:Double-Blind Method; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008137:Longitudinal Studies; D017336:Loratadine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010352:Patient Dropouts; D011446:Prospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D012882:Skin Tests; D013997:Time Factors; D016896:Treatment Outcome
D006634:Histamine H1 Antagonists; D017336:Loratadine; D017332:Cetirizine